title: Pathophysiology and Treatment of Hyperhidrosis.
abstract: Primary focal hyperhidrosis is a disease of unknown cause with profuse perspiration of local sites (head, face, palms, soles of feet, and axillae) that adversely affects daily life. Guidelines have been proposed in the USA [<citeref rid="ref1">1</citeref>], Canada [<citeref rid="ref2">2</citeref>], and Japan [<citeref rid="ref3">3</citeref>]. The symptoms impair quality of life, with significant negative effects on daily existence and personal relationships. The current goal in medical practice for patients with hyperhidrosis is to provide guidance and encourage coping skills for a normal daily life, as well as give appropriate advice regarding treatment options. On occasion, in order to improve quality of life, it is necessary to recommend surgical therapy when conservative treatment fails; this requires an understanding of the mechanisms of available treatments and their effects. This paper reviews theories of primary focal hyperhidrosis with regard to pathology, epidemiology, and treatment.
authors: Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
authors: Tomoko
authors: T
authors: Fujimoto
mesh_terms: D000077410:Aluminum Chloride; D017607:Aluminum Compounds / Q000627:therapeutic use*; D001252:Astringents / Q000627:therapeutic use*; D001365:Axilla; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002712:Chlorides / Q000627:therapeutic use*; D006801:Humans; D006945:Hyperhidrosis / Q000503:physiopathology / Q000628:therapy*; D007271:Injections, Intradermal; D007478:Iontophoresis; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009779:Occlusive Dressings; D012535:Scalp; D013562:Sympathectomy
chemical_list: D017607:Aluminum Compounds; D001252:Astringents; D002712:Chlorides; D009465:Neuromuscular Agents; D000077410:Aluminum Chloride; D019274:Botulinum Toxins, Type A